- Bloom Health Partners (BLMH) has announced a leadership transition involving the position of the chief executive officer
- Andrew Morton, Chief Executive Officer of the company, stepped down on September 30, 2022 to pursue other opportunities
- As a result, Rosemary Elliston, COO of the company, has been appointed to the position of Interim CEO
- Morton will continue to support the company as a director
- Bloom Health Partners Inc. is a global platform for diagnostic testing
- Bloom Health Partners Inc. opened trading at $0.19 per share
Bloom Health Partners (BLMH) has announced a leadership transition involving the position of chief executive officer.
Andrew Morton, Chief Executive Officer of the company, stepped down on September 30, 2022, to pursue other opportunities.
As a result, Rosemary Elliston, COO of the company, has been appointed to the position of Interim CEO.
Morton will continue to support the company as a director.
Elliston, an experienced healthcare executive, brings expertise in organizational planning, team development, multimillion-dollar capital projects, and increasing visibility for growth.
“I am looking forward to working with Andrew and the rest of the Board to leverage the strong initial growth period that the company has been able to achieve and continue to transition the company into new market opportunities and further add to shareholder value,” stated Rosemary Elliston, Interim CEO.
“Diagnostic and health tech services is a large and rapidly growing sector, and our goal is to be at the forefront of it,” she added.
The Board of Bloom has expressed its appreciation to Morton for his hard work and dedication, noting that he delivered strong operating results throughout fiscal 2022 and positioned the company for its next phase of growth.
The Board of Directors, Bloom staff and Elliston have noted that they are committed to business continuity and a smooth transition, including ongoing communications to their shareholders and investors.
“We’re excited about the next phase of growth for Bloom, as the company develops additional service offerings,” said Andrew Morton.
“As a director of the company, I look forward to continuing to support the team in executing this transition,” he added.
Bloom Health Partners Inc. is a global platform for diagnostic testing.
Bloom Health Partners Inc. opened trading at $0.19 per share.
